First Look at Combo With Immunotherapy in Untreated mRCC First Look at Combo With Immunotherapy in Untreated mRCC
The immunotherapy atezolizumab in combination with bevacizumab had some ' provocative ' phase 2 results in untreated, advanced renal cell carcinoma.Medscape Medical News
Source: Medscape Radiology Headlines - Category: Radiology Tags: Hematology-Oncology News Source Type: news
More News: Avastin | Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Radiology | Renal Cell Carcinoma